Bladder Tumor Infiltrating Mature Dendritic Cells and Macrophages as Predictors of Response to Bacillus Calmette-Guérin Immunotherapy

Ayari, Cherifa; LaRue, Hélène; Hovington, Hélène; Decobert, Marc; Harel, François; Bergeron, Alain; Têtu, Bernard; Lacombe, Louis; Fradet, Yves

doi:10.1016/j.eururo.2009.01.040

Cited by 105 publications

(75 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most studies consistently found -mainly in peripheral blood -elevated granulocytic and/or monocytic MDSC levels in patients with various cancers, including BCa (35,36), and the levels were often associated with the tumor stage (34), which is in line with our peripheral MDSC data. In tissue, high infiltration of CD68 + tumor-associated macrophages (TAMs) was associated with a poor response to BCG immunotherapy (37). Notably, the beneficial versus deleterious role of the tumor-associated immune contexture (38) might depend on the localization of immune cell subsets, which can be associated with different clinical outcomes according to whether these subsets are assessed in the tumor core versus the invasive margin, or inside versus outside the tertiary lymphoid structures (39).…”

Section: Discussionmentioning

confidence: 99%

ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence

Chevalier

Trabanelli

Racle

et al. 2017

Journal of Clinical Investigation

186

151

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence

Chevalier

Trabanelli

Racle

et al. 2017

Journal of Clinical Investigation

186

151

View full text Add to dashboard Cite

“…It is conceivable that the mDCs we found in the urine of patients under BCG immunotherapy may play a crucial role in the antitumor activity of BCG therapy. They may interact with the NK cells, T cells and other leukocytes and with various cytokines, through a reciprocal cross-talk that activates anti-tumor responses (33,34). Indeed a very recent report showed that bladder tumour mature dendritic cells and macrophages are predictors of response to BCG therapy (34).…”

Section: Discussionmentioning

confidence: 99%

“…They may interact with the NK cells, T cells and other leukocytes and with various cytokines, through a reciprocal cross-talk that activates anti-tumor responses (33,34). Indeed a very recent report showed that bladder tumour mature dendritic cells and macrophages are predictors of response to BCG therapy (34). In the last years there has been a lot of interest in the evaluation of peripheral blood DC subsets, as an improvement in the enumeration methods has been obtained (35).…”

Section: Discussionmentioning

confidence: 99%

Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy

Rossi¹,

Lichtner²,

Iori

et al. 2013

Arch Ital Urol Androl

View full text Add to dashboard Cite

Objectives: Immunotherapy with BCG (Bacille Calmette-Guérin) after transurethral resection of the bladder tumor represents a highly effective primary treatment for intermediate and high-risk superficial bladder cancer. The effectiveness of this therapy has been documented, but its mechanism of action is not clear yet. In the present study, we investigated the changes of dendritic cells (DC) numbers in peripheral blood and urine of patients with superficial bladder cancer undergoing BCG intravescical therapy Material and method: We have enumerated plasmacytoid and myeloid DCs in the peripheral blood and in the urine of patients with bladder cancer in order to clarify the role of these cells in the evolution of the disease and the effect of therapy. DCs in blood and urine samples were assessed using the single-platform TruCOUNT assay with monoclonal antibodies. The study population included 37 healthy donors and 13 patients with diagnosis of primitive superficial bladder cancer. Results: At the time of diagnosis a reduction of blood DCs was found in patients as opposed to healthy donors, while DCs were not found in the urine in the same way as in healthy subjects. Six of these patients were followed before and after weekly and monthly instillations of BCG. In the peripheral blood, we observed an immunological recovery of DCs from the third weekly instillation up to the sixth. In the urine of patients, we didn't find mDCs or pDCs at T0, but we found a statistically significant change from the third instillation up to the sixth. On the contrary, we didn't find mDCs in urine during monthly instillation. Conclusions: DC Count could be used in the monitoring of patients undergoing BCG therapy. Immunological restoration of mDC numbers in peripheral blood and the efflux in urine could be important for confirming the effectiveness of BCG instillation.

show abstract

“…In that study, higher cancer cell TAM counts and higher cancer cell-to-lamina propria TAM ratio were independent prognostic factors for recurrence after BCG. Ayari et al performed a similar study with TAMs and tumor-infiltrating dendritic cells (TIDCs) [37].…”

Section: Cytokinesmentioning

confidence: 96%

Management of BCG Failures in Non-Muscle-Invasive Bladder Cancer

Han

Hong

2009

Korean J Urol

View full text Add to dashboard Cite

Purpose: Bacillus Calmette-Guérin (BCG) intravesical therapy is the standard treatment in high-risk patients with non-muscle-invasive bladder cancer, but a significant number of patients experience recurrence after BCG therapy. Although several treatment options are available for recurrence after BCG therapy, the optimal treatment strategy is still controversial. We reviewed current and promising treatment options after BCG failure. Materials and Methods: A search of published literature using PubMed and meeting abstracts was performed. Results: BCG failures are further subdefined as BCG refractory, BCG resistant, BCG relapsing, and BCG intolerance. Several predictors for BCG response have been studied, but prediction or stratification before therapy seems to be difficult in clinical practice. Novel biomarkers associated with immunologic mechanisms appear to be promising to predict BCG failure. Radical cystectomy is the standard treatment for BCG-refractory disease, but the timing of cystectomy is controversial. BCG maintenance or combination with interferon-α is a promising therapy for BCG resistance or relapse. Some salvage therapies or device-assisted instillations have been also promising, but the efficacy and safety of these novel therapies should be confirmed by large prospective studies before their clinical use in BCG failure. Conclusions: Patients with BCG failure are not a homogeneous group and need to be stratified. Radical cystectomy should be performed without delay in patients with BCG-refractory status, but salvage intravesical therapies may be an alternative in cases without true refractory status. Although BCG and interferon intravesical therapy is promising, more efficient salvage therapy after BCG failure is required. (Korean J Urol 2009;50:1037-1047)

show abstract

Bladder Tumor Infiltrating Mature Dendritic Cells and Macrophages as Predictors of Response to Bacillus Calmette-Guérin Immunotherapy

Cited by 105 publications

References 26 publications

ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence

ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence

Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy

Management of BCG Failures in Non-Muscle-Invasive Bladder Cancer

Contact Info

Product

Resources

About